PMC:7242007 / 4064-4395 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"228","span":{"begin":294,"end":302},"obj":"Species"},{"id":"259","span":{"begin":97,"end":100},"obj":"Species"},{"id":"260","span":{"begin":123,"end":126},"obj":"Species"},{"id":"281","span":{"begin":40,"end":53},"obj":"Disease"},{"id":"282","span":{"begin":57,"end":65},"obj":"Disease"},{"id":"283","span":{"begin":105,"end":110},"obj":"Disease"},{"id":"284","span":{"begin":163,"end":171},"obj":"Disease"},{"id":"285","span":{"begin":234,"end":242},"obj":"Disease"},{"id":"286","span":{"begin":281,"end":293},"obj":"Disease"}],"attributes":[{"id":"A228","pred":"tao:has_database_id","subj":"228","obj":"Tax:9606"},{"id":"A259","pred":"tao:has_database_id","subj":"259","obj":"Tax:10407"},{"id":"A260","pred":"tao:has_database_id","subj":"260","obj":"Tax:10407"},{"id":"A281","pred":"tao:has_database_id","subj":"281","obj":"MESH:D006509"},{"id":"A282","pred":"tao:has_database_id","subj":"282","obj":"MESH:C000657245"},{"id":"A283","pred":"tao:has_database_id","subj":"283","obj":"MESH:C000657245"},{"id":"A284","pred":"tao:has_database_id","subj":"284","obj":"MESH:C000657245"},{"id":"A285","pred":"tao:has_database_id","subj":"285","obj":"MESH:C000657245"},{"id":"A286","pred":"tao:has_database_id","subj":"286","obj":"MESH:D006509"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Heterogeneous data on the prevalence of HBV infection in COVID‐19 and on the interaction between HBV and COVID‐19\nRisk for HBV reactivation with some experimental COVID‐19 therapies (tocilizumab, corticosteroids)\nSome investigational COVID‐19 medications may be contraindicated in HBV‐infected patients with decompensated cirrhosis"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T66","span":{"begin":44,"end":53},"obj":"Disease"},{"id":"T67","span":{"begin":57,"end":65},"obj":"Disease"},{"id":"T68","span":{"begin":105,"end":113},"obj":"Disease"},{"id":"T69","span":{"begin":163,"end":171},"obj":"Disease"},{"id":"T70","span":{"begin":234,"end":242},"obj":"Disease"},{"id":"T71","span":{"begin":322,"end":331},"obj":"Disease"}],"attributes":[{"id":"A66","pred":"mondo_id","subj":"T66","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A67","pred":"mondo_id","subj":"T67","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A68","pred":"mondo_id","subj":"T68","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A69","pred":"mondo_id","subj":"T69","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A70","pred":"mondo_id","subj":"T70","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A71","pred":"mondo_id","subj":"T71","obj":"http://purl.obolibrary.org/obo/MONDO_0005155"}],"text":"Heterogeneous data on the prevalence of HBV infection in COVID‐19 and on the interaction between HBV and COVID‐19\nRisk for HBV reactivation with some experimental COVID‐19 therapies (tocilizumab, corticosteroids)\nSome investigational COVID‐19 medications may be contraindicated in HBV‐infected patients with decompensated cirrhosis"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T10","span":{"begin":183,"end":194},"obj":"Chemical"},{"id":"T11","span":{"begin":196,"end":211},"obj":"Chemical"}],"attributes":[{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A11","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"}],"text":"Heterogeneous data on the prevalence of HBV infection in COVID‐19 and on the interaction between HBV and COVID‐19\nRisk for HBV reactivation with some experimental COVID‐19 therapies (tocilizumab, corticosteroids)\nSome investigational COVID‐19 medications may be contraindicated in HBV‐infected patients with decompensated cirrhosis"}

{"project":"LitCovid-sentences","denotations":[{"id":"T40","span":{"begin":114,"end":212},"obj":"Sentence"},{"id":"T41","span":{"begin":213,"end":331},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Heterogeneous data on the prevalence of HBV infection in COVID‐19 and on the interaction between HBV and COVID‐19\nRisk for HBV reactivation with some experimental COVID‐19 therapies (tocilizumab, corticosteroids)\nSome investigational COVID‐19 medications may be contraindicated in HBV‐infected patients with decompensated cirrhosis"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T15","span":{"begin":322,"end":331},"obj":"Phenotype"}],"attributes":[{"id":"A15","pred":"hp_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/HP_0001394"}],"text":"Heterogeneous data on the prevalence of HBV infection in COVID‐19 and on the interaction between HBV and COVID‐19\nRisk for HBV reactivation with some experimental COVID‐19 therapies (tocilizumab, corticosteroids)\nSome investigational COVID‐19 medications may be contraindicated in HBV‐infected patients with decompensated cirrhosis"}